FLT3 and acute myeloid leukemia: In the de novo AML subgroup of patients receiving glasdegib + LDAC, there was no statistical (p > 0.05) difference in OS for the five genes with a mutational frequency of > 5 mutations: DNMT3A, combined FLT3 (ITD and TKD), IDH1, IDH2I, and RUNX1. No genes in the LDAC alone arm had ≥ 5 mutations.